PMID- 26964395
OWN - NLM
STAT- MEDLINE
DCOM- 20160502
LR  - 20190827
IS  - 0030-6622 (Print)
IS  - 0030-6622 (Linking)
VI  - 118
IP  - 12
DP  - 2015 Dec
TI  - [Adverse Events of Sublingual Immunotherapy in 207 Patients with Japanese Cedar 
      Pollinosis].
PG  - 1429-35
AB  - Sublingual immunotherapy (SLIT) for Japanese cedar pollinosis is effective, 
      however, caution must be exercised against allergen-specific adverse events (AEs) 
      during SLIT. PURPOSE: The purpose of this study was to clarify the AEs of SLIT in 
      a large cohort of patients with Japanese cedar pollinosis. METHODS: We conducted 
      a detailed survey, by both questionnaires and direct interviews, of 207 patients 
      receiving SLIT at our clinic. RESULTS: Eighty-four of the 207 patients (40.5%) 
      developed AEs, with AEs involving the oral cavity and throat being the most 
      common (56 patients; 27.1%). Sixteen patients (7.9%) had local mucosal swelling, 
      but the swelling resolved in all the cases. Other allergen-induced symptoms such 
      as nasal symptoms (29 events, 14.0%), eye symptoms (14 events, 6.8%) and ear 
      symptoms (20 events, 9.7%) were also recognized. All the AEs were minor, and 
      discontinuation of SLIT was not necessitated in any of the patients because of 
      AEs. There were 52 AEs (25.0%) in the up-dose phase and 61 AEs (29.3%) in the 
      maintenance phase. However, only 4 of the 161 patients (2.5%) developed AEs 
      during the pollen season. Most AEs developing during the maintenance phase 
      occurred in the first few weeks. In 60% of the cases, the AEs disappeared within 
      2 weeks, and in 6.0% (5 events), they persisted for longer than 2 months. There 
      were no age-or sex-related differences in the prevalence of cedar pollen-specific 
      IgE, or in the adherence to the treatment. CONCLUSION: AEs in SLIT were shown in 
      many patients, however, the severity of AEs was mild and no events interfered 
      SLIT.
FAU - Ogawa, Yukiko
AU  - Ogawa Y
FAU - Yuta, Atsushi
AU  - Yuta A
FAU - Arikata, Masahiko
AU  - Arikata M
FAU - Kozaki, Hideaki
AU  - Kozaki H
FAU - Ohta, Nobuo
AU  - Ohta N
FAU - Suzuki, Yusuke
AU  - Suzuki Y
FAU - Shimizu, Takeshi
AU  - Shimizu T
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Nihon Jibiinkoka Gakkai Kaiho
JT  - Nihon Jibiinkoka Gakkai kaiho
JID - 7505728
RN  - 0 (Allergens)
SB  - IM
MH  - Administration, Sublingual
MH  - Adult
MH  - Allergens/*administration & dosage
MH  - Child
MH  - Cryptomeria/*immunology
MH  - Female
MH  - Humans
MH  - Immunotherapy/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Rhinitis, Allergic, Seasonal/immunology/*therapy
EDAT- 2016/03/12 06:00
MHDA- 2016/05/03 06:00
CRDT- 2016/03/12 06:00
PHST- 2016/03/12 06:00 [entrez]
PHST- 2016/03/12 06:00 [pubmed]
PHST- 2016/05/03 06:00 [medline]
AID - 10.3950/jibiinkoka.118.1429 [doi]
PST - ppublish
SO  - Nihon Jibiinkoka Gakkai Kaiho. 2015 Dec;118(12):1429-35. doi: 
      10.3950/jibiinkoka.118.1429.